Partner with us

The Institute for Molecular Bioscience is Australia's #1 research institute. We were established to position Queensland as a global epicentre of drug discovery, and to create a full pipeline of capabilities from basic discovery science to translational research, spanning genomics, biology and chemistry.

Our vision is a world free of disease, and our partners are an integral part of this vision. By joining together, we can co-design and deliver new and improved solutions to the problems that face humanity. We have a track record of partnering to deliver translational outcomes. We have created multibillion-dollar spin-out companies developing treatments for stroke, Parkinson's disease and cancer, and helped deliver the world's first bee-friendly, plant-extract bioinsecticide. We have worked with parents and clinicians to diagnose rare genetic diseases in children and partnered with community groups to fight the cane toad infestation. IMB has the expertise and facilities to address globally relevant and organisation-specific research problems. We seek creative approaches to solve problems, and welcome the talent and ideas of our partners.

Contact us

Dr Norbert Kienzle

Dr Norbert Kienzle

Senior Manager - Research Partnerships & Development

  +61 7 334 62082

Our capabilites

We have a broad range of capabilities that span a number of research areas. In particular, we have expertise in:

  • Pharmacogenomics
  • Statistical genetics
  • AI diagnostics
  • Drug discovery
  • Pre-clinical research models
  • Medicinal chemistry

To learn more about our capabilities and expertise in these areas, please contact our Research Partnership team.

Hear from our partners

Download our fast facts              

Institute Molecular Bioscience_Infographic            

Impact areas

Our capabilities and technology enable discovery in our focus areas:

  • Antimicrobial resistance, with a focus on antibiotic discovery
  • Sepsis
  • Cardiovascular disease (atherosclerosis, diabetes)
  • Infectious diseases - malaria, tuberculosis
  • Stroke
  • Pain
  • Endometriosis
  • Motor neurone disease (ALS/MND)
  • Mental health (Alzheimer's, Parkinson's, memory function)
  • Cancer
  • Respiratory infections (viral, bacterial)
  • Non-alcoholic steotohepatitis (NASH)
  • Autoimmune diseases (lupus/SLE)
  • Gastrointestinal and urinary tract infections
  • Ageing and wellbeing

Funding opportunities

Partner with us directly or in collaboration through government funding schemes such as:

  • ARC Industry Fellowships
  • ARC Linkage Projects
  • Innovation Connections
  • CRC Projects
  • NHMRC Partnership Projects
  • NHMRC Development Grants

If you have funding available, we can also undertake contract research.

A protein complex called an inflammasome.

Case study: Inflazome

One of the largest biotech deals in Australian history was the sale of a start-up company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland, including IMB researchers, and Trinity College Dublin.

The company, Inflazome, was acquired by Swiss multinational pharma company Roche for an upfront payment of ~$A600 million, plus additional payments based on the achievement of certain milestones.

Inflazome was founded in 2016 to develop drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes, protein complexes that are understood to drive many chronic inflammatory conditions. The acquisition gives Roche full rights to Inflazome’s portfolio of drugs, which includes candidates in clinical trials.

General enquiries

  +61 7 3346 2222

Partner enquiries

Norbert Kienzle
  +61 7 3346 2192

Support us

Donate to research
100% of donations go to the cause